- Home
- ETON vs ORIC Comparison
ETON vs ORIC Comparison
Compare ETON & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- ORIC
- Stock Information
- Founded
- ETON 2017
- ORIC 2014
- Country
- ETON United States
- ORIC United States
- Employees
- ETON N/A
- ORIC N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- ETON Health Care
- ORIC Health Care
- Exchange
- ETON Nasdaq
- ORIC Nasdaq
- Market Cap
- ETON 428.5M
- ORIC 362.9M
- IPO Year
- ETON 2018
- ORIC 2020
- Fundamental
- Price
- ETON $17.21
- ORIC $5.13
- Analyst Decision
- ETON Strong Buy
- ORIC Strong Buy
- Analyst Count
- ETON 3
- ORIC 9
- Target Price
- ETON $27.67
- ORIC $18.00
- AVG Volume (30 Days)
- ETON 221.4K
- ORIC 650.1K
- Earning Date
- ETON 05-13-2025
- ORIC 05-05-2025
- Dividend Yield
- ETON N/A
- ORIC N/A
- EPS Growth
- ETON N/A
- ORIC N/A
- EPS
- ETON N/A
- ORIC N/A
- Revenue
- ETON $39,011,000.00
- ORIC N/A
- Revenue This Year
- ETON $92.33
- ORIC N/A
- Revenue Next Year
- ETON $52.62
- ORIC N/A
- P/E Ratio
- ETON N/A
- ORIC N/A
- Revenue Growth
- ETON 23.29
- ORIC N/A
- 52 Week Low
- ETON $3.18
- ORIC $3.90
- 52 Week High
- ETON $18.41
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- ETON 70.21
- ORIC 48.72
- Support Level
- ETON $16.43
- ORIC $4.52
- Resistance Level
- ETON $17.49
- ORIC $5.83
- Average True Range (ATR)
- ETON 0.85
- ORIC 0.49
- MACD
- ETON 0.18
- ORIC 0.09
- Stochastic Oscillator
- ETON 98.09
- ORIC 63.51
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.